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Background: Invasion of host erythrocytes by Plasmodium falciparum is central to the pathogenesis of malaria.
Invasion involves recognition events between erythrocyte receptors and ligands on the merozoite, the invasive
blood form of the parasite. Identifying and characterizing host-parasite interactions is impeded by the biochemical
challenges of working with membrane-embedded glycoprotein receptors. For example, the interaction between P.
falciparum erythrocyte binding antigen 175 (PfEBA175) and glycophorin A (GYPA) depends on post-translational
modifications that are not easily added in recombinant expression systems, and the use of native GYPA is limited
by the hydrophobic transmembrane region, making it difficult to biochemically manipulate. It would, therefore, be
desirable to perform quantitative binding assays with receptors embedded within the membranes of intact human
erythrocytes.
Methods: The extracellular region of GYPA was over-expressed as a soluble protein in HEK293E cells. This protein
was characterized, sialylated and evaluated for binding to the PfEBA175 protein. The label-free and free-solution assay,
backscattering interferometry (BSI), was used to perform binding assays of two well-characterized P. falciparum invasion
ligands to intact unmodified human erythrocytes.
Results: Findings indicate that the post-translational modifications present on native GYPA are required for it
to bind recombinant PfEBA175 and that these modifications cannot be recapitulated in vitro using mammalian
overexpression methods. Here, BSI was used to obtain quantitative, high fidelity interaction determinations on
intact, unmodified erythrocytes. Using BSI and purified recombinant proteins constituting the entire ectodomains
of the P. falciparum merozoite ligands PfEBA175 and PfRH5, KDs of 1.1 μM and 50 nM were measured for the
PfRH5-BSG and PfEBA175-GYPA interactions, respectively, in good agreement with previous biophysical
measurements of these interactions.
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Conclusions: These results demonstrate that BSI can be used to detect and quantify the interactions of two
merozoite invasion ligands with their receptors on intact human erythrocytes. BSI assays were performed on
unlabelled, free-solution proteins in their native environment, requiring only nanomoles of recombinant protein.
This study suggests that BSI can be used to investigate host-parasite protein interactions without the limitations
of other assay platforms, and therefore represents a valuable new method to investigate the molecular mechanisms
involved in erythrocyte invasion by P. falciparum.
Keywords: Backscattering interferometry, Biosensors, Glycophorin A, PfEBA175, Basigin, PfRH5, Plasmodium falciparum,
Merozoite, Recombinant proteins, MalariaBackground
Malaria is an infectious disease caused by several species
of protozoan parasites belonging to the Plasmodium
genus, although just one species, Plasmodium falcip-
arum, is responsible for the vast majority of human
mortality and morbidity. About half of the world’s popu-
lation live in regions that are described as being at risk
of malaria, with approximately one million deaths attrib-
uted to this disease annually [1]. Plasmodium parasites
are transmitted to the human host through the bite of
an infected mosquito and, after a largely asymptomatic
liver stage, are released as merozoites, initiating the
blood stage of infection. It is during this stage that the
symptoms of malaria are exhibited. Once within the
blood, P. falciparum merozoites recognize and invade
host erythrocytes where they multiply and, after ruptur-
ing the host cell, are released to begin another cycle of
invasion. Since erythrocyte invasion by the P. falciparum
merozoite is an essential step in the parasite lifecycle,
considerable research has been aimed at understanding
the molecular mechanisms for the invasion process [2]
with the ultimate aim of developing anti-malarial drugs
and vaccines [2-4].
It is known that the invasion of erythrocytes by the mer-
ozoite involves a series of extracellular molecular recogni-
tion events between host receptors and parasite ligands.
For P. falciparum, several host-parasite receptor-ligand in-
teractions have been described which include the interac-
tions between glycophorin A (GYPA) and erythrocyte
binding antigen (EBA)175 [5-8] and those between basigin
(BSG) and reticulocyte binding-like homologue (RH)5 [9].
Despite this progress, the molecular mechanisms of inva-
sion are not completely understood and further progress
will be facilitated by the application of new methods, espe-
cially since the strategies used to date have largely relied
on erythrocytes from patients with rare blood groups
[6,10-12]. Working with erythrocyte cell surface proteins,
however, is technically challenging due to the genetic
intractability of the anucleate erythrocyte and difficul-
ties in solubilizing amphipathic membrane proteins in
their native conformation. Furthermore, extracellular
protein interactions can be highly transient – oftenhaving half-lives of just fractions of a second [13]. To
address these challenges, a method called AVEXIS (for
AVidity-based EXtracellular Interaction Screen) was de-
veloped which detects even very weak interactions be-
tween the entire ectodomains of receptor proteins
expressed as soluble recombinant proteins in mamma-
lian cells [14]. This approach, together with other ad-
vances in the expression of full-length, active P.
falciparum recombinant proteins [15,16], allowed the
successful identification of two new erythrocyte-merozoite
interactions [9,17]. This progress aside, the majority of the
proteins located on the surface of the P. falciparum mero-
zoite have no known binding partner [2].
The lack of knowledge about these parasite proteins
can be largely attributed to technical limitations of exist-
ing approaches that modify the interacting species, or
require removing the membrane protein from its native
environment [18]. Surface plasmon resonance (SPR) and
biolayer interferometry (BLI) have exhibited only a lim-
ited number of successes with membrane proteins due
to the need to immobilize one of the binding partners
and their inherent mass sensitivity. Micro-scale thermo-
phoresis (MST) [19] normally requires removing the
protein from the native environment, and the AVEXIS
technique is not suitable for proteins where the extracel-
lular region cannot be expressed as a soluble recombin-
ant protein - such as those that span the membrane
multiple times; for example, transporters or channels.
With over 50 different multi-span membrane proteins
detectable on human erythrocytes [20], many potential
host receptors are therefore excluded from the AVEXIS
approach. Also, AVEXIS, SPR, BLI, and MST are not
generally suitable to detect interactions with receptors
that are formed by two or more proteins within the
membrane. Finally, and as demonstrated here, the require-
ment to express the proteins recombinantly in a heterol-
ogous cell line can result in the absence of cell-specific,
post-translational modifications that are essential for lig-
and binding. With this in mind, a technique that can sen-
sitively and quantitatively measure interactions between
Plasmodium proteins and their receptors on the surface of
intact erythrocytes would be particularly useful.
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tive, label-free and free-solution assay technology that is
compatible with a wide array of complex matrices [21].
This unique interferometer is based on illuminating a
100 × 210-μm dimensioned semicircular channel in a
microfluidic chip with coherent light from a laser to
create a pattern of light that is interrogated in the back-
scatter configuration [22]. This pattern of light - the
interference pattern - has periodic dim and bright spots
(fringes) whose positions are related to the refractive
index (RI) of the fluid in the channel. When molecules
interact, the compound formed has a distinct and differ-
ent RI than either of, or the sum of, the RI for the reac-
tants. These changes in RI are a consequence of the
conformation, hydration and electron density changing
when the ligand binds to the receptor, and induce meas-
urable changes in the position of the interference fringe
pattern. BSI has been used to quantify binding affinities
on systems with KD values ranging from a few picomolar
(pM) to tens of millimolar (mM). BSI is a universal de-
tection method which uses control and reference sam-
ples to enable the quantification of specific binding
reactions, even within highly complex matrices, such as
vesicles prepared from cell membranes [21].
Here, it is shown for the first time that BSI can be
used to detect and quantify low-affinity interactions
between recombinant Plasmodium proteins and their
known receptors natively embedded within the mem-
brane of whole unmodified erythrocytes. These data
demonstrate that composition and environment are crit-
ical when attempting to define the molecular mecha-
nisms involved in erythrocyte invasion. BSI enables
binding studies to be performed on the intact cell, such
that the membrane protein receptors are unaltered and
can form complexes, as they would in vivo. The results
presented here indicate that this BSI-based methodology
represents a new approach to identify and quantify inter-
actions involved in erythrocyte invasion by P. falcip-
arum, particularly those that contain erythrocyte-specific
post-translational modifications.
Methods
Recombinant protein production and purification
Recombinant human GYPA, PfEBA175 and PfRH5
proteins were produced by transient transfection of
HEK293E cells, as described previously [15]. In brief, the
entire ectodomains of PfEBA175 and PfRH5 were
codon-optimized for expression in human cells, and
cloned into expression plasmids that contained both an
N-terminal signal sequence peptide and C-terminal rat
Cd4 domain 3 + 4 and hexa-His tags [23]. In the case of
human GYPA, the endogenous signal peptide was used
and expressed as either an enzymatically biotinylated
form or as a β-lactamase tagged pentamer [15]. Captureof β-lactamase tagged pentamers was measured by ab-
sorbance of a nitrocefin hydrolysis product at 485 nm.
Where appropriate, plasmids encoding the human α-
2,3-sialyltransferase 1 (α2,3 ST, NP_003024.1), which
catalyzes the synthesis of the Neu5Acα2-3Gal sequence
on O-linked glycans, either singly or in combination
with the rat α-2,6-sialyltransferase 1 (α-2,6 ST, NP_
001106815.1), or the human CMP-sialic acid transporter
(SA transporter, NP_006407.1) were co-transfected with
the GYPA expression construct in a 1:5 ratio. When the
SA transporter was co-transfected, the culture medium
was additionally supplemented with 20mM sialic acid
precursor, N-acetyl-D-mannosamine. Expression plas-
mids are openly available from Addgene [24]. Proteins
were purified from spent cell culture supernatant using
HisTrap HP columns (GE Healthcare) on an ÄKTAx-
press instrument (GE Healthcare) as described [17].
Purified proteins were dialyzed extensively against PBS
to replace the imidazole-containing purification elution
buffer.
Backscattering interferometry instrumentation
A backscattering interferometer was assembled and used
essentially as previously described [22]. To summarize,
the instrument is comprised of a helium-neon (He-Ne)
laser, a microfluidic chip and a charge-coupled device
(CCD) camera acting as a linear array detector. The chip
contains flow channels with a semicircular cross-section
that, upon proper illumination with the laser, create an
optical resonance phenomenon. As a result, BSI has a
long effective optical path-length through the sample
leading to high RI sensitivity. The backscattered inter-
ferometric fringe pattern is directed onto the camera,
which in concert with a Fourier analysis programme, is
used to measure the positional shift in the fringes. This
phase value (in radians) is used to define or quantify the
changes in RI between a control and a test sample. Test
and control samples are sequentially introduced into a
microfluidic chip and allowed to reach temperature and
pressure equilibrium (~10 sec), at which point the phase
value is recorded. The relative RI changes between the
test sample and non-binding controls are correlated with
the conformation changes resulting from a molecular
interaction. By fixing the concentration of the receptor
(number of erythrocytes) and sequentially increasing the
concentration of the ligand in endpoint equilibrium
binding assays, the measured phase changes between the
test and control samples can be used to construct bind-
ing isotherms, from which equilibrium dissociation con-
stants (KDs) can be calculated.
Erythrocyte preparation
A-positive erythrocytes (Valley Biomedical) were pre-
pared to 2% haematocrit in RPMI 1640 medium (Gibco)
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Aldrich). Erythrocytes were then incubated for one
hour at 37°C with gentle agitation. Cells were washed
twice with PBS, and resuspended to 1% haematocrit in
PBS-containing protease inhibitors (Roche).Binding assays using BSI
All binding assays were performed at 0.1% haematocrit
in 0.01% (w/v) BSA-PBS buffer containing serial dilu-
tions of the Plasmodium proteins ligands (PfEBA175 or
PfRH5) as appropriate. The BSA in the buffer helped to
decrease adsorption of samples to the channel surface.
All samples were incubated at room temperature for
one hour to allow binding equilibrium to be reached.
Upon injection of each sample, the phase of the fringe
pattern was recorded and phase changes were calcu-
lated by subtracting the phase measurement recorded
for a control sample from a matched test sample. The
channel was washed with 30 μL BSA-PBS buffer be-
tween samples. When required, channels were cleaned
more thoroughly using serial injections of 10 μL
methanol (50% (v/v)), 30 μL water and finally 30 μL
BSA-PBS. Saturation binding curves were generated by
plotting the phase change between test and reference
against the concentration of Plasmodium protein used.
Determination of the equilibrium dissociation constant
(KD) was carried out by fitting the saturation-binding
isotherm as a square hyperbolic using GraphPad Prism
software.
To quantify the binding of PfEBA175 to GYPA on in-
tact erythrocytes, either neuraminidase-treated cells or
erythrocytes pre-incubated with an anti-GYPA mono-
clonal antibody were used as reference samples. In both
cases, the responses of these references were subtracted
from phase values obtained from untreated erythrocytes
to obtain the phase change due to binding. For anti-
body blocking, erythrocytes were incubated with a final
concentration of 100 μg/mL BRIC256 (Abcam) at room
temperature for one hour, since this antibody had pre-
viously been shown to prevent the binding of PfEBA175
to GYPA [8]. Neuraminidase-treated and antibody-
blocked (control samples) and untreated (test) erythro-
cytes were incubated with a range of concentrations of
PfEBA175 up to 1 μM. Similarly, to quantify the binding
of PfRH5 to BSG on the erythrocyte surface, erythrocytes
were incubated with 10 μg/mL of the MEM-M6/6 anti-
BSG monoclonal antibody (Abcam) at room temperature
for one hour. This antibody is known to block the inter-
action between PfRH5 and BSG and can prevent P. falcip-
arum parasites from invading erythrocytes [9]. Antibody-
blocked (control) and untreated (test) erythrocytes were
incubated with a range of concentrations of PfRH5 up to
4.5 μM.Results
Recombinant glycophorin A expressed in HEK293E cells is
undersialylated and does not bind PfEBA175
The entire ectodomain of PfEBA175 was previously
expressed as a soluble recombinant protein in HEK293E
cells and shown to interact with its receptor, GYPA, on
erythrocytes in a manner that is neuraminidase-sensitive
[8]. While recombinant PfEBA175 protein also bound
native full-length GYPA extracted from erythrocytes,
full-length GYPA is of limited use for in vitro functional
assays because the hydrophobic transmembrane region
makes it difficult to biochemically manipulate. There-
fore, just the extracellular regions of GYPA were
expressed as a soluble recombinant protein in HEK293E
cells. Even though this approach resulted in a highly gly-
cosylated protein of the expected mass (Figure 1A)
which bound anti-GYPA monoclonal antibodies suggest-
ing it was correctly folded, recombinant GYPA did not
bind PfEBA175 (Figure 1B). Since under-sialylation of
recombinant proteins overexpressed in HEK293 cells
has been previously reported [25], it is likely that GYPA
was unable to bind PfEBA175 due to inadequate sialyla-
tion. To increase the level of sialylation of the recombin-
ant GYPA, it was co-transfected with plasmids encoding
α-2,3-sialyltransferase 1, α-2,6-sialyltransferase 1, or the
human CMP-sialic acid transporter. Lectin binding as-
says did show that the level of sialylation of recombinant
GYPA was increased (Figure 1C), yet no treatment was
sufficient to attain the same level of sialylation as is
found in native GYPA (Figure 1D) and they did not bind
to PfEBA175 (Figure 1B).
Taken collectively, these findings demonstrate, at least
in the case of the PfEBA175-GYPA interaction, that the
environment and the post-translational modifications
present on the native protein are critical and required
for ligand binding. This result is perhaps not surprising
given examples within the literature illustrating the often
misleading results that can be obtained when working
with protein fragments or in non-native environments.
For the PfEBA175-GYPA interaction, the ideal approach
would be to employ a method that could quantify
PfEBA175-binding on native GYPA presented on whole,
unmodified erythrocytes. Since BSI showed efficacy for
other membrane protein binding assays, it might be pos-
sible to measure interactions using intact erythrocytes
using this method.
Backscattering interferometry can detect and quantify
PfEBA175 binding to GYPA on whole, unmodified
erythrocytes
BSI is a universal, optical, label-free, free-solution
method and, as such, to quantify specific binding signals,
the response of a non-binding control sample (one that
has the same RI composition except for the binding
Figure 1 Recombinant soluble GYPA expressed in HEK293E cells is undersialylated and does not bind PfEBA175. (A) Denaturing
SDS-PAGE gels of recombinant soluble GYPA, visualized using Coomassie G250 (left panel) and a glycoprotein-specific periodic acid-Schiff
reagent stain (right panel). (B) Recombinant soluble biotinylated GYPA co-expressed without (Rec. GYPA) or with plasmids encoding α-2,3
sialyltransferase 1 (α2,3-ST) singly or in combination with an α-2,6 sialyltransferase 1 (α2,6-ST) or a CMP-sialic acid transporter (SA-Trans) were
immobilized on a streptavidin-coated plate and tested for their ability to bind pentameric β-lactamase-tagged PfEBA175. The positive control
was biotinylated native GYPA and the negative control (−ve) was biotinylated Cd4d3 + 4 alone. (C) Binding of pentameric β-lactamase-tagged
recombinant GYPA and its sialylation-enhanced forms by the three lectins that recognize terminal sialic acids (Neu5Ac) or a subterminal
Galβ1-3GalNAc disaccharide. Negative control was soluble pentameric β-lactamase-tagged Cd4d3 + 4. The assay was a modified version
of AVEXIS with the biotinylated lectins immobilized on a streptavidin-coated plate. (D) Lectin binding to native GYPA and its desialylated
(neuraminidase-treated) form to show extent of sialylation of native GYPA. Figure 1D is reproduced from Wanaguru et al. with minor stylistic
changes [8]. Bars represent mean ± standard deviation (SD), n = 3.
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within complex matrices. Thus, the fringe shift of the
control was subtracted from that of the test sample,
which contains both the target and ligand (see Figure 2
for an explanatory schematic).
Since BSI has never been used to quantify interactions
with endogenously expressed receptors, because of the
high abundance of the GYPA receptor on erythrocytes,
and the inability to detect binding of PfEBA175 to any
of the recombinant forms of GYPA in the AVEXIS assay,
the PfEBA175-GYPA interaction represented a good test
system for a first attempt to use BSI to detect binding of
recombinant protein to native membrane-protein on in-
tact human erythrocytes. The dependence of this inter-
action on the presence of sialic acid [5], facilitated
treating erythrocytes with neuraminidase to produce an
excellent control sample which lacked an active receptor.
Furthermore, pre-coating the erythrocytes with an anti-
GYPA monoclonal antibody, which has previously been
shown to block PfEBA175 binding [8], provided an add-
itional control to increase confidence that the measured
signal was due to a specific interaction.
When the entire extracellular region of PfEBA175,
expressed in HEK293 cells, and purified as a monomeric
Cd4-tagged recombinant protein, (Figure 3A) was com-
bined with untreated whole erythrocytes, a robust BSI
phase change was observed within the ligand dilution
series. To ensure that this interaction was specific and to
quantify the binding signal, we used neuraminidase-
treated erythrocytes as control samples. Subtraction ofthe query and control samples for a dilution series of the
PfEBA175 protein produced a saturation binding iso-
therm (Figure 3B) from which a KD of ~0.05 μM was
calculated. Previously, using the same recombinant
PfEBA175 protein and surface-immobilized GYPA ex-
tracted from erythrocytes and surface plasmon reson-
ance, a KD ~0.26 μM was reported [8]. This five-fold
higher KD is perhaps expected given that BSI is per-
formed in free-solution with the receptor in its native
environment, while the SPR value was derived from a
surface-immobilized membrane protein. Other investiga-
tions have shown that both the physical environment
and tethering can impact KD measurements [26,27],
further emphasizing the advantages of performing mea-
surements on proteins within their native membrane
environment.
To further demonstrate the specificity of the PfEBA175
binding, the anti-GYPA monoclonal antibody, BRIC256,
that blocks binding of PfEBA175 [8] was used as an
additional non-binding control sample. We pre-incubated
the cells with a four-fold excess of a saturating concentra-
tion of BRIC256 prior to adding the PfEBA175. Again,
once the control signal was subtracted from that of the
test sample, a saturable binding response was obtained
(Figure 3B), which is essentially indistinguishable from
that obtained using neuraminidase as the reference. It is
noteworthy that the KDs were found to be equal within
the error of the measurement, as calculated using the two
independent control samples in triplicate each day and on
multiple subsequent days.
Figure 2 Using backscattering interferometry to quantify Plasmodium-host protein interactions on intact, unmodified erythrocytes.
A schematic illustrating how the BSI method was used to detect and quantify Plasmodium-host protein interactions at the surface of intact
erythrocytes. Erythrocytes are used either unmodified (test samples), or modified to produce a non-binding reference (control samples) either by
blocking specific receptors by pre-incubation with monoclonal antibodies (blue ovals), or, in the case of the PfEBA175-GYPA interaction, treated
with neuraminidase. Both the control and test samples are independently incubated with varying concentrations of recombinant soluble Plasmodium
ligands (green crescents) until binding equilibrium is reached and the binding signal is then quantified by backscattering interferometry. For
each ligand concentration, the phase shift response in the control sample is subtracted from that in the test sample and plotted as a function
of the ligand concentration. The equilibrium binding constant is calculated by curve fitting using a square hyperbolic function to the
binding isotherm.
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PfRH5 binding to BSG on whole, unmodified erythrocytes
To further test the utility of BSI to investigate interac-
tions at the surface of intact erythrocytes, the affinity for
PfRH5 binding to its receptor BSG was measured. ThisFigure 3 Backscattering interferometry detects the PfEBA175-GYPA in
ectodomain of PfEBA175 was expressed and purified as a Cd4-tagged monom
staining revealed a single band of the expected size (185 kDa). (B) Quantitatio
using BSI. Erythrocytes that were either neuraminidase-treated (blue squares)
were used as control samples. Data points are means ± SD from three indepeinteraction is of particular interest to the malaria research
community because it is both essential and universally
required by all tested parasite strains for erythrocyte in-
vasion [9]. The PfRH5-BSG interaction is considerably
more challenging to detect than the PfEBA175-GYPAteraction on intact unmodified erythrocytes. (A) The entire
er and resolved under reducing conditions by SDS-PAGE. Coomassie
n of PfEBA175 binding to intact unmodified erythrocytes at equilibrium
or pre-coated with anti-GYPA monoclonal antibody BRIC256 (red circles)
ndent experiments.
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most likely because of the weaker interaction affinity
[8,9], and because BSG is present at a much lower
(~ten-fold) copy number per cell than GYPA [10].
Since BSI has been shown to be exquisitely sensitive,
providing femtomolar detection limits [28] and quantify-
ing picomolar KD values [22], equilibrium binding ana-
lyses were performed on the PfRH5-BSG interaction.
Purified PfRH5 was used as the ligand (Figure 4A), and
erythrocytes pre-incubated with an anti-BSG monoclo-
nal antibody (MEM-M6/6), known to bind erythrocytes
and block the binding of PfRH5 [9] was used as the con-
trol. By using a maximum concentration of PfRH5 that
was four-fold in excess of the measured KD for its recep-
tor, a saturation binding isotherm was obtained from
which a KD of 1.1μM was calculated, a value that is iden-
tical to that previously obtained by SPR using soluble re-
combinant proteins [9] (Figure 4B).
Discussion
The data presented here demonstrate that BSI is well
suited for the detection and quantification of interactions
between P. falciparum merozoite proteins and host recep-
tors at the surface of intact, unmodified erythrocytes. BSI
has numerous advantages over other approaches. First, it
is easy to establish whether the interaction is saturable
(and therefore specific), and does not require any washing
or separation steps that may preclude the detection of
transient interactions (KD ~ μM range, t½ <1 second), a
typical feature of extracellular interactions between
membrane-tethered proteins [13]. Second, BSI can be
used to measure interactions with unaltered cells, pro-
viding erythrocyte receptors embedded in the native
membrane. This advantage is particularly important forFigure 4 Backscattering interferometry detects the PfRH5-BSG interac
expressed and purified as a Cd4-tagged monomer and resolved under red
PfRH5-Cd4 preparation primarily consisted of the unprocessed full-length form
equilibrium using BSI. Erythrocytes that were pre-coated with anti-BSG mono
Data points are means ± SD from seven independent experiments.investigating erythrocyte receptors that are very diffi-
cult to work with biochemically, particularly those that
are formed from multi-chain protein complexes and/or
contain multiple transmembrane-spanning regions. As
demonstrated here, some erythrocyte receptors contain
functionally critical post-translational modifications that
are difficult to faithfully recapitulate using popular expres-
sion systems, necessitating the use of the native protein.
Third, BSI is a label-free technique, so query ligands do
not need to be derivatized with reporter molecules, such
as fluorophores, protein tags or radioactive isotopes.
These reporters lengthen assay time, increase cost and
may interfere with interactions. Fourth, BSI is typically
performed as a free-solution or homogeneous assay, obvi-
ating the requirement for any complex immobilization
chemistry. Finally, because it is based on a microfluidic
channel that has small dimensions (100 × 210μm) protein
sample consumption is constrained, with required quan-
tities in the nanomole to picomole range. Taken collect-
ively, BSI could contribute to malaria research by both
facilitating the use of recombinant, soluble P. falciparum
merozoite protein resources [15,16] to systematically
screen panels of Plasmodium proteins for their ability to
bind erythrocytes, and performing further characterization
of their receptors so as to define their mechanism of
action.
One of the main motivations for exploring the use of
BSI to detect interactions with receptors on the surface
of erythrocytes was the difficulty in detecting binding
between recombinantly expressed GYPA and PfEBA175.
This is most likely due to the undersialylation of GYPA
produced in HEK293E cells. Even with the additional
measures taken to increase sialylation, such as co-
expression with sialyltransferases, recombinant GYPAtion on intact unmodified erythrocytes. (A) Full-length PfRH5 was
ucing conditions by SDS-PAGE. Coomassie staining revealed that the
. (B) Quantitation of PfRH5 binding to intact unmodified erythrocytes at
clonal antibody MEM-M6/6 (red circles) were used as control samples.
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and was unable to bind to PfEBA175. Others have
shown that GYPA expressed in HEK293 cells can bind
to PfEBA175 [29] and so it can be speculated that the
high level expression system based on EBNA1/oriP amp-
lification used here [30] may have saturated the glycosyl-
ation pathway leading to undersialylation.
In regard to the PfEBA175-GYPA interaction, a five-
fold higher equilibrium binding affinity on the surface of
erythrocytes was measured using BSI relative to that
measured using GYPA extracted from cells, biotinylated
and immobilized on a streptavidin-coated surface for
SPR experiments [8]. This higher binding affinity may be
due to the increased mobility of GYPA within the
erythrocyte membrane to form a PfEBA175 receptor.
This observation is also consistent with both structural
[31] and biochemical studies on PfEBA175 [8] which
show that PfEBA175 is capable of forming dimers in so-
lution, and that GYPA forms reversible, non-covalent di-
mers within the erythrocyte membrane [32,33]. These
findings have led to a model whereby a GYPA dimer in-
duces the dimerization of PfEBA175 at the merozoite
surface which may be important for invasion [34]. The
data presented here are consistent with this model, and
suggest that the higher affinity of the PfEBA175-GYPA
interaction, as measured at the erythrocyte surface ra-
ther than when tethered to a solid surface, could be due
to the increased mobility of GYPA within the erythro-
cyte membrane, allowing it to form avid dimers.
The affinity determined here by BSI for the PfRH5-
BSG interaction, with the receptor natively presented on
whole erythrocytes compares very favorably to the values
reported using purified recombinant soluble proteins
and SPR [9,35,36]. This observation might suggest that
the PfRH5 binding site on the erythrocyte surface is en-
tirely contained within the BSG ectodomain and does
not depend on other erythrocyte proteins to act as co-
receptors, such as the BSG-associated monocarboxylate
transporter, MCT1 [37].
Conclusion
BSI is a method capable of detecting and quantifying
molecular interactions at the surface of intact, unmodi-
fied erythrocytes. This technique has great potential as a
tool to investigate the molecular basis of erythrocyte in-
vasion, which will eventually contribute to the design of
new drugs and vaccines to treat and prevent malaria.
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